Literature DB >> 21611890

Anticyclic citrullinated peptide autoantibodies in systemic lupus erythematosus.

Usha Singh1, Sangeeta Singh, Nand K Singh, Pramod K Verma, Suman Singh.   

Abstract

Systemic lupus erythematosus is an autoimmune disease with protean manifestation. Arthritis is one of the most common manifestations seen in SLE. Anti-CCP Ab is a recently described autoantibody that has been claimed as a most sensitive and specific marker for the diagnosis of RA. Study was performed to see whether anti-CCP2 Ab is positive in lupus arthritis or not. Anti-CCP Ab, ANA, ds DNA, and APLA were estimated by ELISA. Anti-CCP2 Ab was positive in 22 cases (37.93%) of SLE. Mean value of anti-CCP (18.08±16.95 U/ml) was statistically significant (P<0.001) when compared to control (5.07±U/ml). A total of 44 (75.86%) patients with SLE had arthritis. In 29 (50.00%) cases, arthritis resembled RA along with classical features of SLE, while 15 cases (25.86%) had nonspecific lupus arthritis. In 13 cases (44.82%) of RA type lupus arthritis, anti-CCP2 Ab was positive, while only three (20%) nonspecific lupus arthritis cases had elevated anti-CCP. In 14 (24.13) patients with SLE, there was no arthritis, but in this group also (6/14) 42.85% cases had elevated anti-CCP. A total of 11 (50%) patients with duration less than 1 year had more anti-CCP 2 positivity when compared to disease duration between 1 and 3 years (27.27%) and disease duration more than 3 years (22.72%), but specifically, it was not significant. Our study concludes that anti-CCP2 is not a specific antibody for RA, but it is present in autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21611890     DOI: 10.1007/s00296-010-1374-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  13 in total

Review 1.  Autoantibodies to citrullinated (poly)peptides: a key diagnostic and prognostic marker for rheumatoid arthritis.

Authors:  Albert J W Zendman; Erik R Vossenaar; Walther J van Venrooij
Journal:  Autoimmunity       Date:  2004-06       Impact factor: 2.815

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

3.  The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.

Authors:  G A Schellekens; H Visser; B A de Jong; F H van den Hoogen; J M Hazes; F C Breedveld; W J van Venrooij
Journal:  Arthritis Rheum       Date:  2000-01

Review 4.  Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients.

Authors:  Yaniv Sherer; Alexander Gorstein; Marvin J Fritzler; Yehuda Shoenfeld
Journal:  Semin Arthritis Rheum       Date:  2004-10       Impact factor: 5.532

5.  Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  R Mediwake; D A Isenberg; G A Schellekens; W J van Venrooij
Journal:  Ann Rheum Dis       Date:  2001-01       Impact factor: 19.103

Review 6.  Anti-CCP Antibody, a Marker for the Early Detection of Rheumatoid Arthritis.

Authors:  Walther J van Venrooij; Joyce J B C van Beers; Ger J M Pruijn
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

Review 7.  Erosive arthropathy: clinical variance in lupus erythematosus and association with anti-CCP case series and review of the literature.

Authors:  J B Martinez; J S Valero; A J Bautista; J F Restrepo; E L Matteson; F Rondon; A Iglesias-Gamarra
Journal:  Clin Exp Rheumatol       Date:  2007 Jan-Feb       Impact factor: 4.473

Review 8.  Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis.

Authors:  Kunihiro Nishimura; Daisuke Sugiyama; Yoshinori Kogata; Goh Tsuji; Takashi Nakazawa; Seiji Kawano; Katsuyasu Saigo; Akio Morinobu; Masahiro Koshiba; Karen M Kuntz; Isao Kamae; Shunichi Kumagai
Journal:  Ann Intern Med       Date:  2007-06-05       Impact factor: 25.391

9.  Does a positive anti-CCP test identify a distinct arthritis entity?

Authors:  Thomas Skogh
Journal:  Arthritis Res Ther       Date:  2005-09-16       Impact factor: 5.156

10.  Presence of antibodies against cyclic citrullinated peptides in patients with 'rhupus': a cross-sectional study.

Authors:  Luis M Amezcua-Guerra; Rashidi Springall; Ricardo Marquez-Velasco; Lorena Gómez-García; Angélica Vargas; Rafael Bojalil
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more
  5 in total

1.  Anti-CCP in systemic lupus erythematosus patients: a cross sectional study in Brazilian patients.

Authors:  Thelma L Skare; Renato Nisihara; Bruno Bandolin Barbosa; Alvaro da Luz; Shirley Utiyama; Vanessa Picceli
Journal:  Clin Rheumatol       Date:  2013-02-15       Impact factor: 2.980

2.  IgG RF and anti-CCP2 antibody can be positive in undifferentiated arthritis due to streptococcal infection, hepatitis B virus, tuberculosis, trauma and hypothyroidism: a preliminary study.

Authors:  Usha Singh; Pamod Kumar Verma; Priyanka Bhagat; Sangeeta Singh; Suman Singh; Nand Kumar Singh
Journal:  Rheumatol Int       Date:  2011-07-26       Impact factor: 2.631

3.  Are anti-CCP antibodies in psoriatic arthritis patients a biomarker of erosive disease?

Authors:  Rodolfo Perez-Alamino; Ignacio Garcia-Valladares; Raquel Cuchacovich; Antonio Iglesias-Gamarra; Luis R Espinoza
Journal:  Rheumatol Int       Date:  2014-02-11       Impact factor: 2.631

Review 4.  Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor.

Authors:  Eng M Tan; Josef S Smolen
Journal:  J Exp Med       Date:  2016-09-12       Impact factor: 14.307

5.  Anti-citrullinated protein antibody response after primary EBV infection in kidney transplant patients.

Authors:  Lianne J N Kraal; Marieke L Nijland; Kristine L Germar; Dominique L P Baeten; Ineke J M Ten Berge; Cynthia M Fehres
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.